BioPoint Inc

BioPoint Inc. is a US-based Life Sciences consulting firm focused in the areas of Drug Safety.

is a US based life sciences consulting organization focused in the areas of Drug Safety, Health Economic

06/18/2026

Campfield launched with $180 million in funding to develop new treatments for inflammatory bowel disease (IBD). The biotech aims to improve outcomes for patients with chronic gastrointestinal conditions. https://www.biospace.com/drug-development/new-biotech-campfield-emerges-with-180m-to-reshape-ibd-treatment

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

06/16/2026

Alto Neuroscience received additional support for its depression drug from an independent study showing positive effects on mood. The findings strengthen confidence in the therapy’s potential. https://www.biospace.com/drug-development/altos-depression-candidate-bolstered-by-independent-study-showing-mood-benefits

Alto Neuroscience is advancing a depression drug based on the dopamine agonist pramipexole, which an independent study has found to help boost feelings of pleasure in patients with mood disorders.

06/15/2026

Neumora Therapeutics is discontinuing a depression drug and reducing staff after two late-stage trial failures. The company is shifting focus to prioritize other pipeline programs. https://www.biospace.com/drug-development/neumora-discards-depression-asset-lays-off-staffers-after-pair-of-late-stage-flops

Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

06/11/2026

Takeda Pharmaceutical Company reported that its AI-designed psoriasis pill outperformed Sotyktu in a head-to-head trial. The results highlight the growing potential of AI-driven drug development. https://www.biospace.com/drug-development/takedas-ai-designed-pill-bests-bms-sotyktu-in-head-to-head-psoriasis-trial

Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.

06/10/2026

Disc Medicine reported that an FDA meeting established a clear regulatory path for its rare blood disease drug. The update improves the drug’s prospects for future approval. https://www.biospace.com/fda/discs-fda-meeting-sets-clear-path-for-embattled-rare-blood-disease-drug

The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

06/09/2026

Eli Lilly reported strong data for its oral GLP-1 drug Foundayo and submitted it to the FDA for diabetes approval. The results further strengthen Lilly’s position against Novo Nordisk in the GLP-1 market. https://www.biospace.com/drug-development/ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approval

Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials. Eli Lilly will seek approval in this indication.

06/08/2026

Revolution Medicines and Tango Therapeutics reported a 92% response rate in a pancreatic cancer combination study. The results highlight strong potential for the experimental treatment. https://www.biospace.com/drug-development/wow-revmed-and-tangos-pancreatic-cancer-combo-hit-92-response

After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.

06/05/2026

Eli Lilly and Company and Novo Nordisk highlighted new obesity data at ADA 2026 as competition in the weight-loss market intensifies. Other drugmakers are also advancing programs to challenge the market leaders. https://www.biospace.com/lilly-novo-face-off-at-ada-2026-as-others-seek-to-compete-in-obesity

The American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

06/04/2026

Massachusetts life sciences employment declined in 2025, ending a 14-year streak of industry job growth. The slowdown reflects broader challenges facing the biotech sector. https://www.biospace.com/job-trends/massachusetts-life-sciences-employment-dipped-last-year-following-14-years-of-growth-report

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

06/03/2026

Travere Therapeutics signed a deal worth up to $1.1B to expand its rare kidney disease portfolio. The agreement strengthens its presence in the rare disease market. https://www.biospace.com/deals/travere-beefs-up-rare-kidney-disease-portfolio-with-up-to-1-1b-china-deal

Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.

Address

13 Centennial Drive Ste. 1
Peabody, MA
01960

Website

http://www.biopointinc.com/

Alerts

Be the first to know and let us send you an email when BioPoint Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BioPoint Inc:

Shortcuts

Want your practice to be the top-listed Clinic in Peabody?